GLG News by Multiple Myeloma Physicians

Analysis of RNA obtained from hair follicles can be used to guide drug development and therapy

".... a major federal study of more than 10,000 middle-aged and older people with Type 2 diabetes (DM) has found that lowering blood sugar actually increased their risk of death, researchers reported Wednesday."

GSK's oral topotecan was favorably reviewed in Europe for treatment of recurrent small cell cancer. IV topotecan is used in ovarian cancer , sarcomas, an rarely in hematological malignancies. The indication is quite narrow and oral use is complicated by lack of re-imbursement and poor patient...

In a phase II trial , Pfizer's Sutent produced an overall response arte of 11 % as second line treatment for patients with non-small cell lung cancer. The response rates is similar to approved agents for recurrent patients with an oral "targeted " drug and favorable safety profile. The role would be...

Sutent is demonstrating some activity in Lung cancer Sutent is unique in this regard versus other TKIs ? I would focus on the FELT for obvious reasons

Hematde is a new ESA with potential benefit over older ESAs hematide may look especially god coming off some of the recent FDA concerns abiut ESAs

New oral agents to replae previous iv meds will not likelty succeed in near future in US patient's are less compliant with oral meds, even for cancer

An oral version of Topotecan that can be used 2nd line in SCLCA. Impact?

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) is pressing for approval of Velcade in a first line rather than second line + setting. This would definitely increase sales

Takeda is collaborating with Effamax to conduct a phase I trial investigating a new erythropoeitin stimulating agent  ( ESA) in anemic patients with refractory solid tumors receiving chemotherapy. The study is well designed and if the new agent has efficacy of Aranesp ( Amgen) and Procrit ( J&...